

Comments regarding this application must be received not later than March 20, 1995.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Oconomowoc Bancshares, Inc.*, Oconomowoc, Wisconsin; to become a bank holding company by acquiring 80 percent of the voting shares of First Bank of Oconomowoc, Oconomowoc, Wisconsin.

Board of Governors of the Federal Reserve System, February 17, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-4548 Filed 2-23-95; 8:45 am]

BILLING CODE 6210-01-F

Susquehanna Bancshares, Inc., et al.; Acquisitions of Companies Engaged in Permissible Nonbanking Activities

The organizations listed in this notice have applied under § 225.23(a)(2) or (f) of the Board's Regulation Y (12 CFR 225.23(a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated for the application or the offices of the Board of Governors not later than March 9, 1995.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105:

1. *Susquehanna Bancshares*, Lititz, Pennsylvania; to acquire Atlanfed Bancorp, Inc., Baltimore, Maryland (a thrift holding company), and thereby indirectly acquire Atlantic FSB, Baltimore, Maryland, and engage in owning, controlling or operating a savings association, pursuant to § 225.25(b)(9) of the Board's Regulation Y; originating loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y; investment advisory services, pursuant to § 225.25(b)(4) of the Board's Regulation Y; real estate appraisal services, pursuant to § 225.25(b)(13) of the Board's Regulation Y; retail securities brokerage, pursuant to § 225.25(b)(15)(i) of the Board's Regulation Y; retail securities brokerage in combination with investment advisory services, pursuant to §§ 225.25(b)(15)(ii) and (b)(4) of the Board's Regulation Y; and providing real estate settlement services, pursuant to *Norwest Corporation*, 80 FRB 453 (1994). The geographic scope of these activities is Maryland.

2. *Susquehanna Bancshares*, Lititz, Pennsylvania; to acquire Reisterstown Holdings, Inc., Reisterstown, Maryland (a thrift holding company), and thereby indirectly acquire Reisterstown FSB, Reisterstown, Maryland, and engage in owning, controlling or operating a savings association, pursuant to § 225.25(b)(9) of the Board's Regulation Y; making and servicing loans including real estate settlement services, pursuant to § 225.25(b)(1) of the Board's Regulation Y and *Norwest Corporation*, 80 FRB 453 (1994); investment advisory services, pursuant to § 225.25(b)(4) of the Board's Regulation Y; sale of credit insurance in the form of mortgage insurance disability and life insurance products to customers of affiliates, pursuant to § 225.25(b)(8)(i) of the Board's Regulation Y; retail securities brokerage, pursuant to § 225.25(b)(15)(i) of the Board's Regulation Y; retail securities brokerage in combination with investment advisory services, pursuant to § 225.25(b)(15)(ii) of the Board's Regulation Y. The geographic scope for these activities is Maryland.

B. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. *F & M National Corporation*, Winchester, Virginia; to acquire Farland Investment Management, Inc., Winchester, Virginia, and thereby engage in portfolio investment advice and financial planning services to individuals, corporations, banks, pension and profit sharing plans, trusts, estates, and charitable organizations, pursuant to § 225.25(b)(4)(iii) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, February 17, 1994.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95-4549 Filed 2-23-95; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Regional Public Hearing of the Commission on Research Integrity in Chicago, IL

Pursuant to Pub. L. 92-463, notice is hereby given of a regional public hearing and meeting of the Commission on Research Integrity, respectively on Thursday and Friday, March 9 and 10, 1995, at the De Paul University, Chicago, IL. On the 9th, the Commission will meet from 8:30 a.m. until 11:15 a.m. at the De Paul Center on 1 East Jackson Boulevard. The afternoon session, 12:30 p.m. until 5 p.m., will be held in the De Paul University Administration Center, 9th floor, on 243 South Wabash Avenue. The sessions will be open to the public and will continue on the 10th from 9 a.m. to 4:45 p.m. at 249 South Wabash Ave. Interested parties are advised to call the Executive Secretary shortly before the meeting to verify the date, place, and agenda.

The mandate of the Commission is to develop recommendations for the Secretary of Health and Human Services (DHHS) and the Congress on the administration of section 493 of the Public Health Service Act, as amended by and added to by section 161 of the NIH Revitalization Act of 1993.

In its deliberations, the Commission has confirmed that there are no quick and easy answers for fair, effective, and realistic administrative solutions to a number of issues in scientific misconduct and research integrity. An essential component of the Commission's information-gathering is to interact extensively with all relevant constituencies of the scientific community—including junior and senior scientists, witnesses,

respondents, academic administrators, as well as students—to understand their particular experiences and perspectives and to explore possible improvements.

Three major areas are currently of great interest to the Commission:

1. *A New Definition of Research Misconduct.* The Commission believes that any definition needs to address the full extent of serious research misconduct, but must avoid a definition that is too broad, vague, and potentially unfair. In addition, a two-tiered approach for research integrity, or failures thereof, would be useful; it would emphasize institutional responsibility, and reserve an oversight role for the Federal Government.

2. *Assurance for Institutions and Accountability for Federally-Funded Research.* The Commission is considering that each institution receiving Federal funds develop and submit for Federal review and approval assurances concerning the establishment and implementation of: (a) Good research practices and professional norms; (b) procedures for disseminating that information throughout its community; and (c) educational activities designed to foster practice of the highest ethical standards in the conduct of research for all researchers. Topics affecting good research practices that might be addressed in institutional assurances include: data recording and retention; supervisory responsibility; authorship practices; protection of witnesses; and other professional conduct bearing directly on the integrity of Federally supported research.

3. *Bill of Rights for Witnesses.* Testimony from witnesses (also called "whistleblowers") who had challenged perceived research misconduct reaffirms the Commission's mandate to propose effective whistleblower protection rules. Witnesses have stated that retaliation occurs with sufficient frequency and impact to have a chilling effect on potential witnesses throughout the research community. The Commission is considering a Witness Bill of Rights and procedures for its implementation.

The Commission will also continue its discussion of other issues on which the Commission is planning to make recommendations in its final report.

The Commission is inviting oral or written statements from interested parties. Lengthy statements exceeding 10 or 15 minutes of oral presentation should be submitted in writing to the Executive Secretary before or at the meeting. Each statement will be reviewed by Commission Members.

Henrietta D. Hyatt-Knorr, Executive Secretary, Commission on Research

Integrity, at Rockwall II, Suite 700, 5515 Security Lane, Rockville MD 20852, (301) 443-5300 or (301) 443-9369 (voice mail), will furnish the Committee charter, a roster of the Committee members upon request, a preliminary report of the Commission, and a meeting agenda upon request. Members of the public wishing to make presentations should contact the Executive Secretary. Depending on the number of presentations and other considerations, the Executive Secretary will allocate a reasonable timeframe for each speaker.

Henrietta D. Hyatt-Knorr,

Executive Secretary, Commission on Research Integrity.

[FR Doc. 95-4550 Filed 2-23-95; 8:45 am]

BILLING CODE 4160-17-P

Agency for Health Care Policy and Research

Filing of Annual Reports of Federal Advisory Committees

Notice is hereby given that, pursuant to Section 13 of the Federal Advisory Committee Act (5 U.S.C. App. 2), the Annual Reports prepared for the public by the committees set forth below have been filed with the Library of Congress:

Health Care Policy and Research Special Emphasis Panel
Health Care Technology Study Section
Health Services Research and Developmental Grants Review Committee
Health Services Research Dissemination Study Section
National Advisory Council for Health Care Policy, Research and Evaluation

Copies of these reports, prepared in accordance with Section 10(d) of the Federal Advisory Committee Act, are available to the public for inspection at: (1) The Library of Congress, Special Forms Reading Room, Main Building, on weekdays between 9 a.m. and 4:30 p.m.; and (2) the Information Resource Center, Agency for Health Care Policy and Research, Suite 501, 2101 East Jefferson Street, Rockville, Maryland, on weekdays between 9 a.m. and 4:30 p.m.

Copies may be obtained from Mr. James E. Owens, Committee Management Officer, Agency for Health Care Policy and Research, Suite 601, 2101 East Jefferson Street, Rockville, Maryland 20852.

Dated: February 14, 1995.

Clifton R. Gaus,

Administrator.

[FR Doc. 95-4551 Filed 2-23-95; 8:45 am]

BILLING CODE 4160-90-P

Agency for Health Care Policy and Research Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2) announcement is made of the following special emphasis panel scheduled to meet during the month of March 1995:

Name: Health Care Policy and Research Special Emphasis Panel.

Date and Time: March 9-10, 1995, 8:30 a.m.

Place: Holiday Inn Crowne Plaza, 1750 Rockville Pike, Parklawn Room, Rockville, Maryland 20852.

Open March 9, 8:30 a.m. to 9:30 a.m.

Closed for remainder of meeting.

Purpose: This Panel is charged with conducting the initial review of grant applications on research that will provide convincing evidence for or against the effectiveness and cost effectiveness of alternative interventions used to prevent, diagnose, treat, and manage common clinical conditions.

Agenda: The open session of the meeting on March 9, from 8:30 a.m. to 9:30 a.m. will be devoted to a business meeting covering administrative matters. During the closed session, the committee will be reviewing grant applications dealing with complex, clinical medical effectiveness issues in response to the medical treatment effectiveness PORT II initiative. In accordance with the Federal Advisory Committee Act, 5 U.S.C., Appendix 2 and 5 U.S.C., 552b(c)(6), the Administrator, Agency for Health Care Policy and Research, has made a formal determination that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Gerald E. Calderone, Ph.D., Agency for Health Care Policy and Research, Suite 602, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594-2462.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: February 16, 1995.

Clifton R. Gaus,

Administrator.

[FR Doc. 95-4552 Filed 2-23-95; 8:45 am]

BILLING CODE 4160-90-M

Health Care Financing Administration [OPL-004-N]

Medicare Program; Meeting of the Practicing Physicians Advisory Council

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Notice of meeting.